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Abstract
Background:  Breast cancers (BC) in women carrying mutations in BRCA1 gene are more
frequently estrogen receptor negative than the nonhereditary BC. Nevertheless, tamoxifen has
been found to have a protective effect in preventing contralateral tumors in BRCA1 mutation
carriers. The identification of the second human estrogen receptor, ERβ, raised a question of its
role in hereditary breast cancer. The aim of this study was to assess the frequency of ERα, ERβ,
PgR (progesterone receptor) and HER-2 expression in breast cancer patients with mutated BRCA1
gene and in the control group.
Methods: The study group consisted of 48 women with BRCA1 gene mutations confirmed by
multiplex PCR assay. The patients were tested for three most common mutations of BRCA1
affecting the Polish population (5382insC, C61G, 4153delA). Immunostaining for ERα, ERβ and PgR
(progesterone receptor) was performed using monoclonal antibodies against ERα, PgR
(DakoCytomation), and polyclonal antibody against ERβ (Chemicon). The EnVision detection
system was applied. The study population comprised a control group of 120 BC operated
successively during the years 1998–99.
Results: The results of our investigation showed that BRCA1 mutation carriers were more likely
to have ERα-negative breast cancer than those in the control group. Only 14.5% of BRCA1-related
cancers were ERα-positive compared with 57.5% in the control group (P < 0.0001). On the
contrary, the expression of ERβ protein was observed in 42% of BRCA1-related tumors and in 55%
of the control group. An interesting finding was that most hereditary cancers (75% of the whole
group) were triple-negative: ERα(-)/PgR(-)/HER-2(-) but almost half of this group (44.4%) showed
the expression of ERβ.
Conclusion: In the case of BRCA1-associated tumors the expression of ERβ was significantly higher
than the expression of ERα. This may explain the effectiveness of tamoxifen in preventing
contralateral breast cancer development in BRCA1 mutation carriers.
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Background
In 1990 Hall et al. discovered that familial breast cancer is
associated with a defect in one of the genes located in the
17q21 chromosome [1]. This finding began a new era of
research into hereditary breast cancer and consequently
led to the identification of the BRCA1 and BRCA2 sup-
pressor genes in 1994 and 1995, respectively. Although
the structures and localization of the BRCA1 and BRCA2
genes differ, their functions seem to be similar because
their transcripts are involved in the same processes [2-6].
These genes are responsible for maintaining the proper
course of the cell cycle, for the repair of DNA damage, and
are also instrumental in the process of cell differentiation.
BRCA1  is also partially responsible for the activity of
estrogen receptors (ER) and, when mutated, can inhibit
the functions of these receptors [7].
BRCA1 and BRCA2 gene mutation carriers are at risk of
developing breast cancer earlier than other patients. Breast
cancer associated with this mutation has characteristic his-
topathological features: (i) the expression of estrogen and
progesterone receptors is less frequently demonstrable,
(ii) the grade of histopathological malignancy is higher
and (iii) accumulation of p53 protein is observed more
often than in sporadic cases of this malignancy [8,9].
Although these factors are usually associated with a
poorer prognosis, their role in BRCA1 and BRCA2 muta-
tion carriers is still controversial [10-15].
The role of tamoxifen in preventing the development of
contralateral breast cancer in BRCA1 mutation carriers is
not fully understood since it significantly reduces that risk
despite low expression of ER [16]. The mechanism
responsible for that has not been yet explained and estro-
gen receptor β may play a role here.
Estrogen receptor β (ERβ) was discovered in 1996 and was
given its name in order to differentiate it from the previ-
ously known type of estrogen receptor (now named estro-
gen receptor α – ERα) [17,18]. The two estrogen receptors
belong to a family of ligand-regulated transcription fac-
tors. They are transcripts of different genes sharing some
structural similarities. When co-expressed, ERα and ERβ
may form homo- or heterodimers upon binding specific
ligands. As dimers, ERs are able to start transcription activ-
ity in two ways: through direct binding to specific regions
of DNA, or through protein-protein interaction with other
transcription factors. In the case of co-expression of both
ERs, their roles may overlap. In certain situations, how-
ever, ERβ opposes the activity of ERα via the inhibition of
ERα-mediated gene expression. These differences are also
observed in the response to tamoxifen. This selective
estrogen receptor modulator may work as a pure ER antag-
onist for ERβ, while it may have a partially agonistic effect
for ERα [19]. In spite of increasing knowledge regarding
the structure and in vitro activity of ERα and ERβ, their
clinical role is still controversial and unclear [20].
For a better understanding of the functions of ERβ we
explored its expression in BRCA1 mutation carriers and
looked for coexistence patterns with other hormonal
receptors (ERα, PgR) and HER-2 receptor.
Methods
The study group included 48 patients with mutations in
the BRCA1 gene. The control group consisted of 120 sub-
sequent breast cancer cases diagnosed over the period of
1998–1999. Patients from both groups underwent breast
surgery from which specimens for histological and immu-
nohistochemical testing were obtained. The study was
approved by the local Bioethics Committee at the Medical
University in Poznań.
Results of genetic tests were obtained from the Prophylac-
tics and Epidemiology Center in Poznań. In the search for
mutations in the BRCA1 gene, tests were performed on
DNA isolated from peripheral blood lymphocytes using a
commercially available kit. They were carried out for three
most common mutations of BRCA1  gene affecting the
Polish population (5382insC, C61G, 4153delA). In
Poland those three mutations in BRCA1 account for 86%
of all BRCA1 and BRCA2 mutations. In the search for
5382insC and 4153delA mutations, the ASA-PCR method
was used. For the detection of C61G mutation, the RELP-
PCR method was applied.
Histological and immunohistochemical tests were com-
pleted in the Department of Tumor Pathology of the Med-
ical University in Poznań. From formalin fixed and
paraffin embedded specimens, 4 μm sections were cut and
mounted onto positively charged glass microscope slides
(Superfrost Plus, Menzel-Glaser, Germany). The sections
were deparaffinized, rehydrated and subjected to antigen
retrieval in citrate buffer in a microwave oven. The slides
were then incubated in 3% hydrogen peroxide for 10 min-
utes to block endogenous peroxidase activity.
The primary antibodies used for immunostaining were as
follows:
1. for ERα – a monoclonal mouse antibody clone 1D5
(Dako, Glostrup, Denmark; code No M 7047) was used at
1:50 dilution and slides were incubated at room tempera-
ture for 1 h;
2. for ERβ – a polyclonal rabbit antibody in which immu-
nogen corresponds to NH2-terminus of the human ERβ,
and, according to the manufacturer, the sequence used is
conserved in all known isoforms (Chemicon Interna-
tional, Temecula, CA; catalog No AB1410). This antibodyBMC Cancer 2008, 8:100 http://www.biomedcentral.com/1471-2407/8/100
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was used at a dilution of 1:500 and overnight in an incu-
bation chamber at 4°C;
3. for PgR – a monoclonal mouse antibody clone PgR636,
(Dako, Glostrup, Denmark; code M 3569) was used at a
dilution of 1:100 and slides were incubated at room tem-
perature for 1 h. This antibody (according to the manufac-
turer) has been demonstrated by Western blot to react
with both forms of the progesterone receptor: the PR-A
and PR-B.
The antibody reactions were revealed using Dako EnVi-
sion™+System-HRP. Subsequently the slides were incu-
bated in DAB chromogen for 5 minutes at room
temperature. The sections were counterstained with
hematoxylin, and coverslipped.
Immunostained slides were evaluated by two independ-
ent observers in a "blinded" fashion, using light micros-
copy. Tumors were considered to be expressing receptors
if a positive reaction (regardless of its intensity) was iden-
tified in at least 10% of the cancer cells' nuclei.
HER-2 protein was identified by means of the HecepTest™
kit (Dako). Tumors were classified as 0, 1+, 2+ or 3+ on
the basis of the spread and intensity of membranous
staining in invasive portions of the cancer. Tumors show-
ing staining reactions in class 3+ were considered to be
over-expressing HER-2. In the case of the 2+ results
obtained, suggestive of over-expression of the HER-2 pro-
tein, amplification of the c-erbB2 gene was tested by the
application of fluorescent in-situ hybridization (FISH).
Cases with an immunohistochemistry result of 2+ but
without amplification of the gene, as tested by FISH, were
not considered to be over-expressing HER2.
To assess dependences Fisher' Exact Test (for 2 × 2 contin-
gency tables) and the Fisher-Freeman-Halton (for larger
Table 1: Clinicopathological characteristics of patient cohorts
Parameter BRCA1-associated breast cancers n = 48 Control group n = 120 P-value
Age
median (range) 45 (29 – 68) 57 (38 – 85) <0.0001
Age > 50 years 16 (33%) 82 (68%)
Histological type
invasive ductal 42 (87%) 103 (85.8%) 0.7993
invasive lobular 1 (2%) 10 (8.3%) 0.14
medullary like 5 (10%) 0 < 0.001
other 0 9 (7.5%) < 0.001
Tumor grade
I 1 (2.0%) 36 (29%) <0.001
II 11 (22.9%) 53 (44.1%) 0.0122
III 27 (56.2%) 26 (21.7%) <0.0001
unknown 9 (18.7%) 5 (4.2%) 0.0017
Tumor size
median 2.2 3.0 0.14
≤ 2 cm 28 (58.3%) 53 (44.1%) 0.102
> 2 cm ≤ 5 cm 16 (33.3%) 50 (41.6%) 0.282
> 5 cm 3 (6.2%) 17 (14.1%) 0.147
unknown 1 (2.0%) 0
Lymph node
negative 34 (70.8%) 52 (43.3%) 0.001
positive ≤ 3 8 (16.6%) 38 (31.6%) 0.015
positive >3 4 (8.3%) 22 (18.0%) 0.104
unknown 2 (4.1%) 8 (6.6%)
Bilateral breast cancer 13 (27.1%) 2 (1.7%) <0.0001
Mutation:
5382insC 37 (77.5%)
C61G 10 (20.4%)
4153delA 1 (2%)BMC Cancer 2008, 8:100 http://www.biomedcentral.com/1471-2407/8/100
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contingency tables) test were applied. Significance was
accepted at P < 0.05.
Results
The clinicopathological characteristics of breast cancer
patients with mutated BRCA1 gene and those of the con-
trol group are shown in Table 1. BRCA1 gene mutations in
the study group were identified as follows: 5382insC
(77.5%), C61G (20.4%) and 4153delA (2%).
The average age of patients with mutations in the
BRCA1gene was 45 years, and 57 years in the control
group.
Invasive ductal carcinoma (no special type) was found to
occur at the same frequency in both the BRCA1-positive
group as well as the control group (87% and 85.8%,
respectively). Other tumor types were much less frequent,
although it is noteworthy that all 5 patients with "medul-
lary like" carcinoma came from the BRCA1 mutation car-
riers group (10%).
The assessment of histological malignancy was performed
according to the Bloom-Richardson classification and
showed that patients carrying BRCA1  mutations devel-
oped grade 3 tumors more often and had less frequent
metastases to axillary lymph nodes.
In the BRCA1-positive group, the rate of patients who
developed bilateral breast cancer accounted for 27.1% (13
cases). In the control group, bilateral breast cancer was
found in 2 patients only (1.7%).
The presence of estrogen receptor α was detected in the
tumors of 7 (14.5%) patients with BRCA1gene mutations
and in 69 patients (57.5%) in the control group (Fig. 1).
For progesterone receptors, the figures were 6 (12.5%)
and 77 (64%), respectively. The expression of estrogen
receptor β was detected in the tumors of 20 (42%) of the
BRCA1-mutation patients and in 66 (55%) of the subjects
in the control group (Table 2) (Fig. 2).
In the group with BRCA1 mutations, the most frequently
found phenotype was ERα(-)/ERβ(-) observed in 52% of
patients, followed by ERα(-)/ERβ(+) noticed in 33.3%
cases. In the control group only 14.2% of the patients pre-
sented phenotype ERα(-)/ERβ(+). The most common
phenotype observed in that group was ERα(+)/ERβ(+) –
40.8% (Table 3).
The over-expression of the HER-2 receptor in patients
with mutated BRCA1 genes was observed only in 3 cases
(6.2%). In the control group over-expression of HER-2
was found in 20 cases (16.7%).
An interesting finding of this study is that most hereditary
cancers have been found to be triple-negative: ERα(-)/
PgR(-)/HER-2(-). Such a phenotype was found in 36
cases, which accounts for 75% of the whole group of
patients with a mutated BRCA1 gene. 16 patients in that
group expressed ERβ and presented the following pheno-
type: ERα(-)/PgR(-)/HER2(-)/ERβ(+). In the control
group, the triple-negative phenotype was found in 24
patients (20%) of whom 5 had tumors expressing ERβ.
Discussion
In our study, patients with BRCA1 gene mutations were
tested for the expression of steroid receptors (ERβ, ERα
ERα immunostaining on paraffin-embedded invasive breast  cancer using 1D5 Dako antibody (40× magnification) Figure 1
ERα immunostaining on paraffin-embedded invasive breast 
cancer using 1D5 Dako antibody (40× magnification).
Table 2: Receptor status in BRCA1-associated breast cancer and in cancer of the control group
Expression of steroid receptors BRCA1-associated breast cancers n = 48 Control group n = 120 P-value
n( % ) n ( % )
ERα(+) 7 14.5 69 57.5 <0.0001
ERβ(+) 20 42 66 55 0.129
PgR(+) 6 12.5 77 64 <0.0001
HER2(+) 3 6.2 20 16.7 0.064BMC Cancer 2008, 8:100 http://www.biomedcentral.com/1471-2407/8/100
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and PgR) and the HER-2 receptor in breast cancer tissue.
In this group, ERβ was more common (42%), while ERα
and PgR occurred less frequently (14.5% and 12.5%
respectively). In the control group, the expression of ERα
and PgR was 57.5 and 64%, respectively. In the case of
ERα and PgR, the differences between the two groups were
found to be statistically significant (p = 0.001). Those val-
ues are similar to those described by other authors
[8,12,21,22]. In the case of ERβ, however, the differences
of expression between those two groups were small.
Most of our control group patients were tested for the
presence of BRCA1 mutations. Although those tests were
not performed on all the controls, this cannot influence
the overall findings of the study since in Poland BRCA1
mutations (unselected for age) occur only in about 3% of
all breast cancer patients [23].
It has been pointed out in many studies that BRCA1 posi-
tive breast cancers rarely express ERα [8-12,20,21]. Fur-
ther confirmation of that observation comes from recent
studies made with the use of the cDNA microarray tech-
nique, showing that breast cancers may vary considerably
in their molecular profile [24,25]. The largest group con-
sists of tumors with a cellular profile matching that of the
inner layers of the mammary glands, such as luminal cells
(luminal types) and another group consists of tumors
with basal cell profiles (basal types). These two groups dif-
fer in their expression of ERα. The luminal types express
ERα, while the basal types usually do not. cDNA studies
of breast cancers with underlying BRCA1 gene mutations
show that the most common cancer type in this group is
basal [26]. Moreover, basal type tumors show expression
of receptors for epidermal growth factor (EGFR) more
often. Generally, about half of the patients with BRCA1
gene mutations present the phenotype ER(-)/HER2(-)/
EGFR(+) of the basal type of tumor, which is usually asso-
ciated with poor prognosis [26-28]. On the other hand,
there are data that suggest that the prognosis for BRCA1-
positive patients is no worse than that for patients without
mutations [10-14]. This discrepancy may suggest the
influence of some incompletely explored prognostic and
predictive factor(s).
Recent analyses suggest that ERβ may be an independent
prognostic and predictive factor in the course of breast
cancer [29-33]. However, its role has not yet been fully
discovered. It is noteworthy that in our clinical material
(in contrast to ERα) the expression of the ERβ in tumor
tissues of patients with BRCA1 gene mutations is almost
as frequent as in the non-hereditary breast cancer patients.
It would be interesting to test whether frequent represen-
tation of ERβ in BRCA-positive tumors is actually respon-
sible for the earlier reported activity of tamoxifen in the
reduction of contralateral breast cancer risk.
Fan et al. showed that there is a link between estrogen
receptors and the BRCA1 protein. In an in vitro study,
BRCA1 protein proved to be one of the transcription reg-
ulators for active ERα. The transcription co-activator p300
plays an important role in this process, and its presence
correlates with the ability of the BRCA1 protein to sup-
press the activation of ERα transcription [7].
Our study group displayed certain characteristics of hered-
itary breast cancer. One of these features was the young
age of the patients. In this group, the average age of breast
cancer diagnosis was 45 years, 12 years earlier than in the
control group. The same average age at which the diagno-
sis was established, was reported for Spanish families and
a similar age (43 years) in Markus's study of the popula-
tion of Ashkenazi Jews [10]. Age is a well known factor
influencing the expression of ERα. The fact that there was
a 12-year difference in the average age between the BRCA1
gene mutations group and the control group must have
some influence on the reported ERα expression in our
study. Regarding ERβ expression, however, we believe that
difference bears no material significance on the result.
Our opinion is based on the fact that numerous studies
have indicated that the expression of ERβ is not age-
dependent.
In both groups, the most frequent histological diagnosis
was that of ductal carcinoma (87% and 85.8%, respec-
tively). Another common histological type of breast can-
cer found in the mutation carriers group was "medullary
like" carcinoma (10%). In the control group, however,
not a single case of that type of cancer was identified. A
higher rate of "medullary like" carcinoma is typical of
ERβ immunostaining on paraffin-embedded invasive breast  cancer using antibody from Chemicon (40× magnification) Figure 2
ERβ immunostaining on paraffin-embedded invasive breast 
cancer using antibody from Chemicon (40× magnification).BMC Cancer 2008, 8:100 http://www.biomedcentral.com/1471-2407/8/100
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BRCA1 mutation carriers and this diagnosis is associated
with a relatively good prognosis [34,35]. Consequently, it
was believed that this diagnosis positively affected the
prognosis for BRCA1-positive patients. Unfortunately, a
recent study failed to confirm that finding [36].
Patients with hereditary disease have been found to
develop bilateral breast cancer more often. Our study has
confirmed this observation as it has been found that bilat-
eral breast cancer affected 13 patients of the study group
(27.1%).
The above characteristics of hereditary breast cancer have
been frequently described in the literature and are consist-
ent with the previously published data. Little, however,
has been said regarding the expression of ERβ. This
appears to have been mentioned only once in a letter to
the Editor of the Journal of Clinical Oncology which
reported on estrogen receptor-beta expression in heredi-
tary breast cancer where positive staining for ERβ was
detectable in 94% (15 of 16) of BRCA1 associated breast
cancers [37].
In our study, ERβ expression was present in 42% of
BRCA1 mutation carriers. This seems to be important as it
may explain the protective effect of tamoxifen in the pre-
vention of contralateral tumor development in BRCA1
mutation carriers.
Out of the hereditary cancer patients in our study group,
75% were found to be triple-negative, lacking ERα, PgR
and HER-2 over-expression. Unfortunately, at the current
state of the art, neither hormonal therapy, nor immuno-
therapy (trastuzumab) in an adjuvant setting, can be
offered to those patients.
Gruvberger-Saal et al [38] reported that the expression of
ERβ is an independent marker for favourable prognosis
after adjuvant tamoxifen treatment in ERα negative breast
cancer patients. Bearing in mind that as many as 44% of
the triple-negative patients in our study expressed ERβ, we
propose that hormone therapy might be used in the treat-
ment of BRCA1 mutation carriers expressing the ERα(-)/
PgR(-/HER2(-)/ERβ(+) phenotype.
The results obtained in our study show that the expression
of ERβ in BRCA1 gene mutation carriers is statistically
higher than the expression of ERα. This may be why
tamoxifen has proven to be effective in preventing the
development of contralateral breast cancer in BRCA1
mutation carriers. Consequently, testing patients carrying
BRCA1 mutations for the presence of ERβ might help to
identify those who could benefit from endocrine therapy.
Conclusion
In the case of BRCA1-associated tumors the expression of
ERβ was significantly higher than the expression of ERα.
This may explain the effectiveness of tamoxifen in pre-
venting contralateral breast cancer development in BRCA1
mutation carriers.
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